Compare · BIS vs HCXY
BIS vs HCXY
Side-by-side comparison of ProShares UltraShort Nasdaq Biotechnology (BIS) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIS and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.54B.
- Over the past year, BIS is down 57.8% and HCXY is down 1.0% - HCXY leads by 56.8 points.
- HCXY has hit the wire 2 times in the past 4 weeks while BIS has been quiet.
ProShares UltraShort Nasdaq Biotechnology
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Latest BIS
Latest HCXY
- Hercules Capital’s Investment Adviser Surpasses $2.3 Billion in Investable Capital
- Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
- Hercules Capital Reports Second Quarter 2026 Financial Results
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
- Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
- Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team